Session 2: Particle Engineering to Address Formulation Challenge

Category : Session 2: Particle Engineering to Address Formulation Challenge

Addressing poor solubility and oiling-out tendencies of drug substances

By Dr. Lotfi Derdour, Ph.D. Associate director, GlaxoSmithKline In recent years, there has been a increase in challenges related to low solubility1 and propensity for oiling-out2 in active pharmaceutical...

Dr. Lotfi Derdour, GlaxoSmithKline

Lotfi completed his Bachelor’s degree in Chemical Engineering as top student in 1993 from University of Science and Technology, Oran, Algeria. He then obtained his master’s in Industrial Chemistry...

Use of automation, dynamic image analysis, and process analytical technologies to enable data rich particle engineering efforts at the Drug Substance / Drug Product interface: A case study using Lovastatin

By Dr. Jeremy M. Merritt, Ph.D. Senior director and Group leader, Eli Lilly & Co. Automation plays a vital role in reducing development time in the pharmaceutical industry, both...

Dr. Jeremy M. Merritt, Eli Lilly & Co.

Jeremy M. Merritt (merrittje@lilly.com) is currently a Senior director and group leader at Eli Lilly and Co. in the synthetic molecule design and development organization (SMDD). He joined Lilly...

Office Address

Pinterest

Social List

Category : Session 2: Particle Engineering to Address Formulation Challenge

Addressing poor solubility and oiling-out tendencies of drug substances

Dr. Lotfi Derdour, GlaxoSmithKline

Use of automation, dynamic image analysis, and process analytical technologies to enable data rich particle engineering efforts at the Drug Substance / Drug Product interface: A case study using Lovastatin

Dr. Jeremy M. Merritt, Eli Lilly & Co.